Ligand Pharmaceuticals (NASDAQ:LGND) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ligand Pharmaceuticals stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Ligand Pharmaceuticals Price Performance

Shares of LGND stock traded down $0.24 during trading hours on Thursday, reaching $207.85. The company had a trading volume of 175,173 shares, compared to its average volume of 223,545. Ligand Pharmaceuticals Incorporated has a 12-month low of $97.48 and a 12-month high of $227.92. The company has a debt-to-equity ratio of 0.44, a quick ratio of 21.98 and a current ratio of 22.23. The company has a market capitalization of $4.14 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 2.46 and a beta of 1.14. The stock has a fifty day moving average of $198.34 and a 200-day moving average of $194.04.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.56. The firm had revenue of $59.67 million for the quarter, compared to the consensus estimate of $55.59 million. Ligand Pharmaceuticals had a return on equity of 13.86% and a net margin of 46.42%.The firm’s revenue was up 39.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.27 earnings per share. Ligand Pharmaceuticals has set its FY 2026 guidance at 8.000-9.000 EPS. On average, equities analysts anticipate that Ligand Pharmaceuticals Incorporated will post 1.73 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada lifted its holdings in shares of Ligand Pharmaceuticals by 25.8% in the 1st quarter. Royal Bank of Canada now owns 6,120 shares of the biotechnology company’s stock worth $644,000 after acquiring an additional 1,256 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Ligand Pharmaceuticals in the 1st quarter valued at approximately $344,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Ligand Pharmaceuticals by 8.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,660 shares of the biotechnology company’s stock valued at $1,121,000 after purchasing an additional 809 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Ligand Pharmaceuticals by 9.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 55,327 shares of the biotechnology company’s stock worth $5,817,000 after purchasing an additional 4,926 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Ligand Pharmaceuticals by 176.2% during the first quarter. Jane Street Group LLC now owns 36,922 shares of the biotechnology company’s stock worth $3,882,000 after purchasing an additional 23,553 shares in the last quarter. Hedge funds and other institutional investors own 91.28% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on LGND. HC Wainwright lifted their price target on Ligand Pharmaceuticals from $231.00 to $239.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Royal Bank Of Canada raised their price objective on shares of Ligand Pharmaceuticals from $234.00 to $235.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Stifel Nicolaus boosted their target price on shares of Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Oppenheimer increased their price target on shares of Ligand Pharmaceuticals from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Finally, Bank of America assumed coverage on shares of Ligand Pharmaceuticals in a report on Wednesday, March 11th. They set a “buy” rating and a $244.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $245.86.

Insider Transactions at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $202.23, for a total value of $94,441.41. Following the completion of the transaction, the director directly owned 42,253 shares of the company’s stock, valued at $8,544,824.19. The trade was a 1.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Reardon sold 5,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $201.24, for a total transaction of $1,006,200.00. Following the sale, the insider owned 41,382 shares in the company, valued at $8,327,713.68. This trade represents a 10.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 30,915 shares of company stock valued at $6,385,917. Corporate insiders own 7.00% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.